10:43 AM EST, 02/05/2025 (MT Newswires) -- Acrivon Therapeutics ( ACRV ) said Wednesday the US Food and Drug Administration has granted its ACR-368 OncoSignature Assay Breakthrough Device designation.

The assay is designed to identify endometrial cancer patients who are likely to respond to the company's ACR-368 treatment, the company said. The designation accelerates the product's development, assessment, and review for approvals.

Shares of Acrivon Therapeutics ( ACRV ) were up nearly 21% in recent Wednesay trading.

Price: 7.15, Change: +1.24, Percent Change: +20.98